We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu
Trial record 1 of 7 for:    connect for cancer prevention
Previous Study | Return to List | Next Study

Connect for Cancer Prevention Study (Connect)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04609072
Recruitment Status : Recruiting
First Posted : October 30, 2020
Last Update Posted : May 25, 2023
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) )

Brief Summary:


The National Cancer Institute, part of the National Institutes of Health, has partnered with nine health care systems across the U.S. to establish the Connect for Cancer Prevention Study. While researchers have made important discoveries, there is more to learn to lower the number of people affected by cancer. By taking part in Connect, participants can help researchers learn how the way we live, our genetics, and our health history may affect cancer risk.


To study and better understand the causes of cancer and to find new ways to prevent it.


The study will include 200,000 adults who get their health care from a partner health care system, are between 40 and 65 years old at enrollment, and have never had cancer. People remain eligible to join if they have or once had non-melanoma skin cancer, or a condition that may raise cancer risk (such as ductal carcinoma in situ, or DCIS).


Eligible recruits can sign up for Connect online by creating an account on the MyConnect app using their email address or phone number. After creating an account, they will complete the informed consent process. All information shared through the MyConnect app is secure to protect participant privacy. After joining the study, participants will be asked to answer online health surveys a few times a year, donate samples of blood, urine, and saliva every two to three years, and safely share access to their electronic health records with Connect. In the future, participants may donate unused samples that are collected at clinical visits, like tissue, stool, or blood, and may mail in samples collected at home. Participants may also share information from personal health trackers, like wearable devices or apps.

This information will help researchers study the health and behavior patterns that may affect cancer risk.

It takes time to understand the causes of cancer, so Connect will go on for many years. The longer people participate, the more researchers may learn. Participants can leave the study at any time.

Learn more about Connect by visiting cancer.gov/connectstudy.

Condition or disease
Cancer General Research Use

Show Show detailed description

Layout table for study information
Study Type : Observational
Estimated Enrollment : 200000 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Connect for Cancer Prevention Study: A Prospective Cohort Study Within Integrated Healthcare Systems in the US
Actual Study Start Date : July 26, 2021
Estimated Primary Completion Date : December 31, 2070
Estimated Study Completion Date : December 31, 2070

Healthy volunteers
Up to 200,000 men and women aged 40 to 65 years, with no personal history of cancer, and patients or members of participating integrated health care systems.

Primary Outcome Measures :
  1. cancer incidence, progression, and mortality [ Time Frame: year one and onward ]
    cancer incidence, progression, and mortality outcomes could include, but are not limited to:early biological effects (e.g., inflammation or metabolomic markers) related to cancer, intermediate biomarkers, cancer precursors, cancer risk factors, cancer incidence, cause of death, cancer survival, risk of second cancers and survivorship

Secondary Outcome Measures :
  1. general research use [ Time Frame: year zero and onward ]
    The endpoints are limitless and could include methodological research, human biology, ancestry, evolution or health-related outcomes.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   40 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Patients or members of participating health care organizations around the U.S.

Due to the minimal risk nature of this protocol, all individuals interested and able to participate in Connect for Cancer Prevention, who meet the eligibility criteria and are not specifically excluded, will be able to participate. In order to be eligible to participate in this study, an individual must meet all of the following criteria:

  • Patients or members of participating IHCS at the time of enrollment
  • Age between 40 and 65 years old at study invitation


  • Individuals with a history of invasive cancer (other than non-melanoma skin cancer)
  • Individuals with known cognitive impairment documented in their medical record

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04609072

Layout table for location contacts
Contact: Nicolas Wentzensen, M.D. (301) 435-3975 ConnectPI@nih.gov

Layout table for location information
United States, Colorado
Kaiser Permanente Colorado Recruiting
Denver, Colorado, United States, 80247
Contact: Heather Feigelson    Not Listed      
United States, Georgia
Kaiser Permanente Georgia Recruiting
Atlanta, Georgia, United States, 30305
Contact: Jennifer Gande    Not Listed      
United States, Hawaii
Kaiser Permanente Hawaii Recruiting
Honolulu, Hawaii, United States, 96814
Contact: Stacey Honda    Not Listed      
United States, Illinois
University of Chicago Medical Center Recruiting
Chicago, Illinois, United States, 60603
Contact: Habibul Ahsan    Not Listed      
United States, Maryland
National Cancer Institute (NCI)- DCEG Recruiting
Bethesda, Maryland, United States, 20892
Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office    888-624-1937      
United States, Michigan
Henry Ford Health Systems Recruiting
Detroit, Michigan, United States, 48202
Contact: Benjamin Rybicki    Not Listed      
United States, Minnesota
HealthPartners Recruiting
Minneapolis, Minnesota, United States, 55425
Contact: Pamela Pawloski    Not Listed      
United States, Oregon
Kaiser Permanente Northwest Recruiting
Portland, Oregon, United States, 97086
Contact: Mark Schmidt    Not Listed      
United States, South Dakota
Sanford Health Recruiting
Sioux Falls, South Dakota, United States, 57117
Contact: Chun-Hung Chan    Not Listed      
United States, Wisconsin
Marshfield Clinic Health System Recruiting
Marshfield, Wisconsin, United States, 54449
Contact: Robert Greenlee    Not Listed      
Sponsors and Collaborators
National Cancer Institute (NCI)
Layout table for investigator information
Principal Investigator: Nicolas Wentzensen, M.D. National Cancer Institute (NCI)
Additional Information:
Layout table for additonal information
Responsible Party: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT04609072    
Other Study ID Numbers: 10000034
First Posted: October 30, 2020    Key Record Dates
Last Update Posted: May 25, 2023
Last Verified: May 23, 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: .All collected Connect IPD will be provided to the scientific community following the governance principles outlined in the protocol.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Analytic Code
Time Frame: Starting in 2023
Access Criteria: Please see Sections 8 and 9.11 of the protocol that address data sharing.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) ):
Risk Factors
medical conditions
Natural History